Update in postmenopausal osteoporosis management


Why we should use tools to evaluate osteoporosis risk? Olivier Bruyère (ULG)

Role of biochemical assessments in the management of osteoporosis. Etienne Cavalier (ULiège) Slides Belgian Menopause society avril 2022

Bisphosphonates vs. denosumab: Advantages and risks. Charlotte Verroken (UGent) Bisphosphonates vs. denosumab

MHT and SERMS for osteoporosis: do they still have a place? Serge Rozenberg (ULB-VUB) BMS osteoporosis 30.4.22 (1)

Satellite symposium UCB Romososumab: Results of trials, positioning and indications Evelien Gielen

Next meeting

Cognitive disorders, depression and work ability at the menopause.

Latest news

Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative (WHI) hormone therapy trials